Is HeartSciences Inc. (HSCS) a Buy, Sell, or Hold?
NASDAQ : HSCS
HeartSciences Inc.
$2.43 USD
-$0.13 (-5.08%)
- Volume
- 17.25K
- Average Volume
- 2.34M
- Market Capitalization
- $5.27M
- P/E Ratio
- -0.61
- Dividend Yield
- 0.00%
- Price Target
- $3.00
- Year High
- $4.30
- Year Low
- $1.63
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.00
| Source | Headline |
|---|---|
|
Fortitude and HeartSciences (Nasdaq: HSCS) Announce Business Combination, Aiming to Bring a Leading Vertically-Integrated Zcash Mining Platform to the Public Markets
FAIRPORT, N.Y.--(BUSINESS WIRE)--Fortitude Mining Holdings, Inc. ("Fortitude"), a vertically-integrated digital asset mining platform anchored in Zcash, and HeartSciences Inc. (Nasdaq: HSCS) (“HeartSciences”), an AI-powered medical technology company, today announced that they have entered into a definitive merger agreement to combine in an all-stock transaction (the “Proposed Transaction”) which is expected to close in H2 2026. Upon closing, the combined company will operate under the Fortitud. businesswire.com - 2026-06-23 07:30:00 |
|
European Patent Granted for ECG-Based Assessment of Diastolic Function, Expands HeartSciences' Patent Portfolio to More Than 45 Granted Patents
Patent covers machine-learning models that use ECG data to estimate echocardiogram parameters indicative of diastolic function Patent covers machine-learning models that use ECG data to estimate echocardiogram parameters indicative of diastolic function globenewswire.com - 2026-06-11 08:30:00 |
|
HeartSciences Launches MyoVista Insights™ Version 1.3 with AI-ECG Algorithm Marketplace and First FDA-Cleared Algorithm
Bunkerhill Health's FDA-cleared ECG-EF algorithm for the detection of reduced ejection fraction becomes the first cleared AI-ECG algorithm available through MyoVista Insights, advancing HeartSciences' SaaS-based, recurring-revenue marketplace strategy Bunkerhill Health's FDA-cleared ECG-EF algorithm for the detection of reduced ejection fraction becomes the first cleared AI-ECG algorithm available through MyoVista Insights, advancing HeartSciences' SaaS-based, recurring-revenue marketplace strategy globenewswire.com - 2026-06-02 08:30:00 |
|
HeartSciences Signs Commercial Agreement with North Shore Health, the First Hospital Deployment from the Cibolo Health Network
Agreement follows Cibolo Health's endorsement of MyoVista Insights for its network of 127 independent hospitals and reflects continued commercial momentum for HeartSciences' ECG management platform Agreement follows Cibolo Health's endorsement of MyoVista Insights for its network of 127 independent hospitals and reflects continued commercial momentum for HeartSciences' ECG management platform globenewswire.com - 2026-05-19 08:30:00 |
|
HeartSciences Signs First SaaS Revenues Agreement following full launch of MyoVista Insights™
Agreement with St. Vincent Health marks HeartSciences' transition from early adopter installations to commercial SaaS deployments following the full launch of MyoVista Insights at the American College of Cardiology Annual Scientific Session Agreement with St. Vincent Health marks HeartSciences' transition from early adopter installations to commercial SaaS deployments following the full launch of MyoVista Insights at the American College of Cardiology Annual Scientific Session globenewswire.com - 2026-05-05 09:00:00 |
|
Analyzing Rennova Health (OTCMKTS:RNVA) & HeartSciences (NASDAQ:HSCS)
Rennova Health (OTCMKTS:RNVA - Get Free Report) and HeartSciences (NASDAQ: HSCS - Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, earnings, valuation, risk and dividends. Analyst Recommendations This is a breakdown of recent defenseworld.net - 2026-04-27 02:06:59 |
